Shilpa Medicare Limited — PPTs, 13-11-2024: Investor Presentation

**Financial Highlights:** Q2 FY25 total revenue reached ₹348.8 crore, marking an 11% increase year-over-year. Growth was primarily driven by strong performance in the emerging markets and licensing within the Formulation segment. Gross profit improved to ₹226.8 crore with a margin of 65%, while EBITDA surged 46% to ₹91.0 crore, representing a margin of 26%. The company achieved a remarkable PAT of ₹18.0 crore, reflecting a 1,008% increase compared to the same quarter last year.

**Strategic Initiatives and Growth Drivers:** Shilpa Medicare is actively expanding its product portfolio with several key launches. The first generic of Nilotinib is set for release in the EU market, and recent approvals for Bortezomib signal ongoing growth potentials in its formulations segment.

**Business Developments:** The company has signed multiple CDMO projects and is experiencing positive outcomes in its biologicals business, which reported a net profit for the first time. Additionally, the acceptance of the NDA for Oxylanthanum Carbonate by the USFDA is a pivotal milestone.

**Market Position and Competitive Advantage:** With a robust pipeline and strong regulatory filings, Shilpa Medicare is well-positioned to leverage its competitive advantages and enhance its global footprint, particularly in oncology and formulations.

**Investor Implications:** Given the strong performance metrics, active business developments, and expanding product range, Shilpa Medicare presents a positive outlook for sustained growth and value creation for investors.